Member Info for neilrich3

....Revenue consensus has increased in recent weeks. 2021 Revenue was £95m, however has increased to £112m. 2022 was £79m, however has been revised upwards to £92m. Moving in the right direction.

Yes, I'd agree more likely to be LFT. Shall be interesting to see whether the Government delay the introduction of LFT for travel off the back of this.

'One scientist said the mystery needs to be looked into “seriously and rapidly” with explanations including faulty tests, people “gaming” tests to induce positive results or the possibility the lateral flows are detecting a new variant which is not being picked up by current PCR tests.'

LFT detecting a new variant?

More than likely a combination of cheap PCR and LFT from abroad, the government been using other than gold standard PCR.

https://twitter.com/NjbBari3/status/1446029665194307585

There was nothing wrong with exsig, would appear that NHS labs could not cope with the lengthy preparation of the samples.

Because it shall streamline the preparation process, I'm expecting a very small inexpensive unit. Previously some customers might have been put off by the labour intensive fiddly preparation process.

CO-prep could well be a game changer for the Q32, looking forward to the video demonstration.

Kaeren, Highly likely that CO-prep has been co developed with Labman Automation, at least I hope so, they've a very good reputation. Also, the Labman HQ is in the same town as IT IS, both are located at Stokesley.
https://www.labmanautomation.com

Hopefully David shall adopt Amryt Pharma's style of reporting and perhaps Quarterly reporting too.

Amryt Reports Record Q2 2021 Results and Raises FY 2021 Guidance

Acquisition of Chiasma completed

Amryt now has three approved commercial products and a robust clinical pipeline

35.9% YoY revenue growth in Q2 to $62.8M

6th consecutive quarter of positive EBITDA generation

Cash increased to $142.9M at June 30 from $118.6M at March 31

Oleogel-S10 NDA accepted by the FDA, Priority Review granted; target PDUFA date set for November 30, 2021

Raising FY 2021 revenue guidance to $210M - $215M, representing 15-18% YoY growth

Checking the financials for Amryt Pharma, David Allmond's employer since April 2017, there's no hiding the fact that they've had an impressive growth in earnings:
2016 - $1.35m
2017 - $12.78m
2018 - $17.09m
2019 - $58.12m
2020 - $182.61m
2021 - £160m (forecast)
2022 - £261m (forecast)

Also, Sept 2020 David was promoted from Chief Commercial Officer to Chief Business Officer.

The last sentence in the description is the only hurdle, I guess that once approved, this shall be the turning point within the USA and when the a Sales/Support team shall be established within North America.

'genesig® kits are sold for research use only and are not licensed for diagnostic procedures'

Few people had heard of PCR before the arrival of COVID, the pandemic has brought the technology to the forefront and POC testing too, there's no going back....simply a waiting game.

Love the Attogene product description and no reference to COVID:
'Guaranteed results using 550 genesig kits
Fast DNA and RNA analysis in less than 60 minutes
Quick and easy set-up and run
Automated data analysis result calling
Small and robust instrument
Exceptional value for money
genesig® kits are sold for research use only and are not licensed for diagnostic procedures.'

Do wonder how many machines are part of the Novacyt inventory. Also, the current rate of production at IT-IS, this would be a better indicator of demand.

UK having the worst infection rate is likely to be due to us performing the most tests.

.....waiting for that large contract to come along and then three large ones all arrive together.

Exciting times ahead, plenty going on behind the scenes which we no nothing about.

https://twitter.com/BiofortunaLtd/status/1430803371632603136

....being Novacyt's UK Manufacturing partner, perhaps further news soon.

What's the betting that DA shall deliver the Q3 trading update on day one, whilst blowing smoke up GM's arse, thanking him for his sterling service. More than likely that the handover is already in progress, DA working for NCYT is his spare time

Wilson, I believe so, PROmate and COprep to be used together, to streamline the process further. I'm guessing that it shall reduce testing turnaround time too. Hopefully the company shall release a video demonstration soon.

Plenty positives within Today's RNS with the launch of the new Winterplex for centralised laboratories and the new Escaplex, clearly the company has done the research and they know that there is a global market for such products.

The news about Home use Antigen LFT delayed to Q4 is neither here or there, astonished by the reaction from some. Expecting David Allmond to hit the ground running, I'm pretty certain that he's already working for the company in his spare time and I think we shall have a much clearer picture post AGM.

Would be interesting to learn initial production capacity at launch, how many units a week for CO-Prep? Also, target retail price.

Clearly there are good reasons why the company has decided not to develop a pro-mate version of Winterplex, however it does not matter, because now we are offering CO-Prep something better than pro-mate. The company states significant interest in the new platform, therefore it would appear that co-prep is likely to be the favoured platform in the future...it makes perfect sense.